Alpha 1 Anti-Trypsin

Inhibitor of neutrophil elastase attenuating airway inflammation

Phase of research

FDA-approved for Other Purpose

How it helps

Anti-Inflammatory

General information

Alpha 1 anti-trypsin is a protease inhibitor naturally present in our cells. It was approved in 2010 by the FDA for medical use and is sold under the brand name Glassia®. It is used to treat congenital deficiency of alpha 1-proteinase. In relation to cystic fibrosis, our AIM tool found the data that alpha 1 anti-trypsin can help reduce airway inflammation in cystic fibrosis patients. 

Alpha 1 Anti-Trypsin on PubChem
Alpha 1 Anti-Trypsin on DrugBank
Alpha 1 Anti-Trypsin on Wikipedia

Synonyms

AAT, alpha-1-proteinase inhibitor

Marketed as

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

results for 120del23 / V232D
See all data on Alpha 1 Anti-Trypsin

Treats

Mutation Link Tested on Impact factor Notes
General effect Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. humans 1.97 Minor effect.
General effect alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. humans 5.35 Minor effect.

Does not treat

Mutation Link Tested on Impact factor Notes